Compare · CVRX vs SYK
CVRX vs SYK
Side-by-side comparison of CVRx Inc. (CVRX) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CVRX and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $125.43B, about 614.7x CVRX ($204.0M).
- Over the past year, CVRX is up 2.8% and SYK is down 10.5% - CVRX leads by 13.3 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- SYK has more recent analyst coverage (25 ratings vs 13 for CVRX).
- Company
- CVRx Inc.
- Stryker Corporation
- Price
- $7.72+0.13%
- $328.42+0.28%
- Market cap
- $204.0M
- $125.43B
- 1M return
- -17.08%
- -1.28%
- 1Y return
- +2.80%
- -10.52%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 5
- 5
- Recent ratings
- 13
- 25
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest CVRX
- CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
- SEC Form DEFA14A filed by CVRx Inc.
- SEC Form DEF 14A filed by CVRx Inc.
- CVRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- CVRx Reports Preliminary First Quarter 2026 Financial Results
- Chief Medical Officer Adamson Philip B. was granted 41,000 shares and sold $9,973 worth of shares (1,262 units at $7.90), increasing direct ownership by 182% to 61,578 units (SEC Form 4)
- CHIEF HUMAN RESOURCES OFFICER Morrison Gregory was granted 34,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Morrison Gregory
- PRES & CEO Hykes Kevin sold $61,349 worth of shares (7,763 units at $7.90) and was granted 159,000 shares, increasing direct ownership by 114% to 284,237 units (SEC Form 4)
- CHIEF MKTG & STRAT OFFICER Verrastro Paul was granted 45,000 shares and sold $10,146 worth of shares (1,284 units at $7.90), increasing direct ownership by 260% to 60,551 units (SEC Form 4)
Latest SYK
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Leerink Partners initiated coverage on Stryker with a new price target
- Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
- Amendment: Stryker Corporation filed SEC Form 8-K: Regulation FD Disclosure
- Stryker to announce financial results for its first quarter of fiscal year 2026
- Stryker names Nick Mead Vice President, Investor Relations
- Amendment: SEC Form SCHEDULE 13G/A filed by Stryker Corporation
- SEC Form 4 filed by Stiles Spencer S
- SEC Form 4 filed by Pierce James Andrew